194 related articles for article (PubMed ID: 36917021)
41. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.
Velickovic M; Delahunt B; Störkel S; Grebem SK
Cancer Res; 2001 Jun; 61(12):4815-9. PubMed ID: 11406557
[TBL] [Abstract][Full Text] [Related]
42. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
Chen YB; Xu J; Skanderup AJ; Dong Y; Brannon AR; Wang L; Won HH; Wang PI; Nanjangud GJ; Jungbluth AA; Li W; Ojeda V; Hakimi AA; Voss MH; Schultz N; Motzer RJ; Russo P; Cheng EH; Giancotti FG; Lee W; Berger MF; Tickoo SK; Reuter VE; Hsieh JJ
Nat Commun; 2016 Oct; 7():13131. PubMed ID: 27713405
[TBL] [Abstract][Full Text] [Related]
43. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
[TBL] [Abstract][Full Text] [Related]
44. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
45. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
46. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
47. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.
Yakirevich E; Madison R; Fridman E; Mangray S; Carneiro BA; Lu S; Cooke M; Bratslavsky G; Webster J; Ross JS; Ali SM
Eur Urol Oncol; 2021 Apr; 4(2):282-288. PubMed ID: 31412008
[TBL] [Abstract][Full Text] [Related]
48. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
[TBL] [Abstract][Full Text] [Related]
49. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
50. Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features.
Ren Q; Wang L; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
Am J Surg Pathol; 2018 Jun; 42(6):767-777. PubMed ID: 29462091
[TBL] [Abstract][Full Text] [Related]
51. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
52. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.
de Velasco G; Wankowicz SA; Madison R; Ali SM; Norton C; Duquette A; Ross JS; Bossé D; Lalani AA; Miller VA; Stephens PJ; Young L; Hakimi AA; Signoretti S; Pal SK; Choueiri TK
Br J Cancer; 2018 May; 118(9):1238-1242. PubMed ID: 29674707
[TBL] [Abstract][Full Text] [Related]
53. How New Developments Impact Diagnosis in Existing Renal Neoplasms.
Akgul M; Williamson SR
Surg Pathol Clin; 2022 Dec; 15(4):695-711. PubMed ID: 36344184
[TBL] [Abstract][Full Text] [Related]
54. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
[TBL] [Abstract][Full Text] [Related]
55. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
[TBL] [Abstract][Full Text] [Related]
56. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
57. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W
Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122
[TBL] [Abstract][Full Text] [Related]
58. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
59. The emerging role of NF2 alterations in new and established subtypes of renal cell carcinoma.
Paintal A; Antic T
Hum Pathol; 2023 Mar; 133():87-91. PubMed ID: 35705112
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
